| 0.719 -0.026 (-3.54%) | 04-20 11:11 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.96 | 1-year : | 1.13 |
| Resists | First : | 0.82 | Second : | 0.96 |
| Pivot price | 0.65 |
|||
| Supports | First : | 0.62 | Second : | 0.5 |
| MAs | MA(5) : | 0.72 |
MA(20) : | 0.64 |
| MA(100) : | 0.79  |
MA(250) : | 0.86 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 93.3 |
D(3) : | 89.4 |
| RSI | RSI(14): 59.3 |
|||
| 52-week | High : | 3.44 | Low : | 0.5 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ TRIB ] has closed below upper band by 18.3%. Bollinger Bands are 8.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.75 - 0.75 | 0.75 - 0.75 |
| Low: | 0.67 - 0.68 | 0.68 - 0.68 |
| Close: | 0.74 - 0.75 | 0.75 - 0.75 |
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Fri, 10 Apr 2026
TRIB Stock Chart | TRINITY BIOTECH PLC-SPON ADR (NASDAQ:TRIB) - ChartMill
Wed, 08 Apr 2026
Trinity Biotech (TRIB) director discloses ADS and option holdings - Stock Titan
Sun, 05 Apr 2026
TRIB SEC Filings - Trinity Biotech Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Fri, 03 Apr 2026
Director John Gillard details ADS option stakes in Trinity Biotech (TRIB) - Stock Titan
Fri, 03 Apr 2026
Interim CFO Paul Murphy listed as insider at Trinity Biotech (TRIB) - Stock Titan
Wed, 01 Apr 2026
TRINITY BIOTECH Q4 2025 Earnings Preview: Recent $TRIB Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 19 (M) |
| Shares Float | 293 (M) |
| Held by Insiders | 17.9 (%) |
| Held by Institutions | 4.5 (%) |
| Shares Short | 291 (K) |
| Shares Short P.Month | 247 (K) |
| EPS | -1.61 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.94 |
| Profit Margin | -75.9 % |
| Operating Margin | -3.6 % |
| Return on Assets (ttm) | -9.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -5.5 % |
| Gross Profit (p.s.) | 0.94 |
| Sales Per Share | 2.56 |
| EBITDA (p.s.) | -0.75 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.47 |
| PEG Ratio | 0.3 |
| Price to Book value | -0.26 |
| Price to Sales | 0.28 |
| Price to Cash Flow | -12.72 |
| Dividend | 1.1 |
| Forward Dividend | 0 |
| Dividend Yield | 148.6% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|